Clinical Trial Update: Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on a modified MRCUKALL XII/ECOG E2993 regimen for acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Snippet

Sponsor: Sun Yat-sen University | Conditions: Leukaemia,Lymphoblastic | Phase 2 | Status: UNKNOWN